Literature DB >> 19536053

Revision bariatric surgery: laparoscopic conversion of failed gastric bypass to biliopancreatic diversion with duodenal switch.

N Trelles1, M Gagner.   

Abstract

With more than 40% failures of gastric bypass in Body Mass Index>50 kg/m2, a successful alternative has to be proposed. Laparoscopic conversion of failed Roux-en-Y gastric bypass to biliopancreatic diversion with duodenal switch is technically feasible, safe and can be performed in 1 or 2 stages. This revision surgery is the most effective treatment to date, and should also be proposed for failed vertical-banded gastroplasty, adjustable gastric banding and Magenstrasse and Mill procedure, as it may provide the most durable weight loss of all revision surgeries with acceptable morbidity. This may result in lesser degrees of hypoproteinemia, commonly seen after distal gastric bypass.

Entities:  

Mesh:

Year:  2009        PMID: 19536053

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  4 in total

1.  Laparoscopic Wedge Resection of Gastrojejunostomy for Weight Recidivism after Gastric Bypass.

Authors:  Aly Elbahrawy; Alexandre Bougie; Mohammad Albader; Rajesh Aggarwal; Sebastian Demyttenaere; Amin Andalib; Olivier Court
Journal:  Obes Surg       Date:  2017-11       Impact factor: 4.129

2.  Pericardial patch ring Roux-en-Y gastric bypass: a preliminary report.

Authors:  Rena Moon; Andre Teixeira; Muhammad A Jawad
Journal:  Obes Surg       Date:  2013-04       Impact factor: 4.129

Review 3.  Revisional bariatric surgery following failed primary laparoscopic sleeve gastrectomy: a systematic review.

Authors:  Douglas Cheung; Noah J Switzer; Richdeep S Gill; Xinzhe Shi; Shahzeer Karmali
Journal:  Obes Surg       Date:  2014-10       Impact factor: 4.129

4.  Revisional Bariatric Surgery for Insufficient Weight Loss and Gastroesophageal Reflux Disease: Our 12-Year Experience.

Authors:  Manabu Amiki; Yosuke Seki; Kazunori Kasama; Kenkichi Hashimoto; Michiko Kitagawa; Akiko Umezawa; Yoshimochi Kurokawa
Journal:  Obes Surg       Date:  2020-05       Impact factor: 4.129

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.